Darzalex Faspro 1800 mg daratumumab and 30,000 units hyaluronidase per 15 mL (120 mg and 2,000 units/mL) injection Images
Generic Name: daratumumab/hyaluronidase
This medication has been identified as Darzalex Faspro 1800 mg daratumumab and 30,000 units hyaluronidase per 15 mL (120 mg and 2,000 units/mL) injection. It is supplied by Janssen Biotech, Inc.
Darzalex Faspro is used in the treatment of Multiple Myeloma; Amyloidosis and belongs to the drug class CD38 monoclonal antibodies. Darzalex Faspro 1800 mg daratumumab and 30,000 units hyaluronidase per 15 mL (120 mg and 2,000 units/mL) injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Darzalex Faspro
- Generic Name
- daratumumab/hyaluronidase
- Strength
- 1800 mg daratumumab and 30,000 units hyaluronidase per 15 mL (120 mg and 2,000 units/mL) injection
- Availability
- Prescription only
- Drug Class
- CD38 monoclonal antibodies
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Janssen Biotech, Inc.
- National Drug Code (NDC)
- 57894-0503
More about Darzalex Faspro (daratumumab / hyaluronidase)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: CD38 monoclonal antibodies
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
